NewsRelease

ResearchArticles Cites HemogloBind™ in Proteomic Analysis of Red BloodCells

MONMOUTHJUNCTION, NJ, April21, 2025 -- Biotech Support Group reports on ajournal article describing the simplicity and efficiency ofHemogloBind™, to remove Hemoglobin prior to LC-MS/MS proteomicanalysis.

Chen,Yaozhen, et al. "Redblood cells undergo lytic programmed cell death involvingNLRP3." Cell (2025).

Thecanonical complement-mediated lysis of mature red blood cells (RBCs)leads to severe pathogenesis. However, inhibition strategiestargeting complement are not always as efficient as expected. In thisstudy, the intracellular events in mature RBCs following complementactivation were investigated. The collected evidence demonstratesthat complement induced hemolysis is a caspase-8-dependent programmedRBC death. To study the downstream signaling of activated caspase-8in mature RBCs, the authors conducted a label-free proteomicanalysis. For this, the article states “Mass-spectrometric analysisof differentially expressed proteins in complement-activated RBCsHuman RBC lysates (from both control and complement-treated groups)were prepared as described previously. Hemoglobin was depleted byadding 250 µl of HemogloBind suspension (Biotech Support Group,Catalog #HO145-05) to each lysate. …the hemoglobin-depletedsupernatant…was then subjected to liquid chromatography-tandem massspectrometry (LC-MS/MS) analysis”. The results compare complementactivation in RBCs with the control group (Figure 4A). Gene Ontology(GO) analysis revealed significant enrichment of pathways associatedwith cytoskeleton organization and actin filament assembly dynamics(Figure 4B). The study concludes that activated caspase-8 directlyinduces the proteolysis of β-spectrin, thereby disrupting theskeletal network of the RBC membrane, a process referred to asspectosis. Spectosis signaling is also activated in autoimmunehemolytic anemia or paroxysmal nocturnal hemoglobinuria, and theinhibition of spectosis significantly reduced complement-inducedhemolysis. These findings reveal a programmed death cascade in matureRBCs, which may have important implications for the treatment ofhemolytic disorders.

“Hemoglobinaccounts for about 95% of the protein mass in red cells. So forproteomics, it is necessary to efficiently remove Hemoglobin butstill recover the vast majority of the remaining red cell proteomefor LC-MS analysis. This is an excellent example of how ourHemoglobin depletion product, HemogloBind™, contributed todifferential proteome analysis of red cells, and that ultimately leadto the conclusions of this study.”states Swapan Roy, Ph.D., President and Founder of BiotechSupport Group.

Clickhere for more information on HemogloBind™

Clickhere for more information on all of our Hemoglobin Removal products

Keywords:Hemoglobindepletion, HemogloBind™, LC-MS/MS,red cell proteomics, programmed cell death, caspase-8, hemolyticdisorders, autoimmune hemolytic anemia, paroxysmal nocturnalhemoglobinuria

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for expanding proteomic analysis.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area. For this market, keyproducts include: AlbuVoid™ and AlbuSorb™ PLUS foralbumin & IgG depletion, Cleanascite™for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobinremoval, and NRicher™ for low abundance and family specific, andtargeted proteome enrichment. For more information, go tohttp://www.biotechsupportgroup.com

Forbusiness development contact: MatthewKuruc
732-274-2866[email protected]